Brief: Kura Oncology & Kyowa Kirin Announce Positive KOMZIFTI Combination Data for acute myeloid
Dec 8 (Reuters) - Kura Oncology Inc KURA.O: KURA ONCOLOGY INC - TRIPLET COMBINATION FOR KOMZIFTI WITH VENETOCLAX AND AZACITIDINE WELL TOLERATED IN NEWLY DIAGNOSED AND R/R SETTINGS KURA ONCOLOGY INC - REGISTRATIONAL TRIALS OF ZIFTOMENIB IN FRONT-LINE AML ONGOING Source text: ID:nGNX2NGx2h Further company coverage: 4151.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia